Highest-materiality recent filing
Jasper Therapeutics initiates strategic review including potential sale or wind-down
Board of Directors initiates comprehensive review of strategic alternatives to maximize shareholder value.
Jasper Therapeutics director Christian Nolet resigns; Svetlana Lucas joins audit committee
Christian Nolet resigned from Board and all committees effective May 15, 2026.
Jasper Therapeutics Q1 net loss $1.2M; refiles Phase 2b protocol for briquilimab in CSU
Cash and equivalents of $14.1M as of March 31, 2026, with $5.8M R&D and $5.1M G&A expenses.
Jasper posts Q4 net loss $9.1M; cash $28.7M; appoints new CEO; reports positive CSU/asthma data
Jeet Mahal named President and CEO to lead next phase of clinical growth.
67% (4/6) of new BEACON briquilimab patients achieved complete response at week 12; mean UAS7 drop of 31 points.
Effective Jan 5, 2026, Jeet Mahal becomes CEO and President; he also joins the Board as Class III director.
Jasper reports positive ETESIAN asthma data; BEACON investigation clears drug product
Single 180mg briquilimab reduced sputum eosinophils from 10.3% to 2.32% at 6 weeks post-allergen challenge.
Jasper Q3 net loss $18.7M; BEACON investigation finds no drug quality issues; cash $50.9M
Net loss of $18.7M ($1.13 per share); R&D expense $14.4M, G&A $4.8M.
Jasper Therapeutics prices $30M public offering, updates BEACON CSU investigation progress
Gross proceeds ~$30M from offering of 11.67M shares + warrants at $2.43/share; closing expected Sept 22.
Jasper Therapeutics Q2 net loss $26.7M; cuts workforce 50%, probes BEACON lot issue
Net loss of $26.7M ($1.74 per share); cash and equivalents $39.5M as of June 30, 2025.
Jasper Therapeutics cuts workforce ~50%, halts non-urticaria programs; CMO departs
Workforce reduction of ~50% and halting of all non-chronic urticaria programs.
8 of 9 (89%) patients in 240mg and 360mg single-dose cohorts achieved complete response (UAS7=0).
Jasper Therapeutics shareholders elect directors, ratify PwC, approve say-on-pay
Elected Kurt von Emster, Scott Brun, and Vishal Kapoor as Class I directors with >8.4M votes each.
Jasper Therapeutics: 92% complete response in 180mg cohort of briquilimab SPOTLIGHT study in CIndU
11 of 12 participants (92%) achieved complete response; 12 of 12 (100%) achieved clinical response within 8-week analysis.
Jasper Therapeutics Q1 2025 net loss $21.2M; cash $48.8M; briquilimab programs on track
Net loss of $21.2M ($1.41 per share) for Q1 2025; R&D expenses $16.2M, G&A $5.6M.
Company entered Open Market Sale Agreement with Jefferies LLC to sell up to $100M of common stock.
Jasper Therapeutics reports FY2024 net loss of $71.3M; briquilimab data positive
Cash and equivalents $71.6M at Dec 31, 2024; net loss $71.3M ($4.89 diluted EPS) for FY2024.
Mean UAS7 change of -26.6 at 8 weeks in 240mg single-dose cohort (N=3); all patients achieved Complete Response (UAS7=0).
Jasper Therapeutics Q3 net loss $18.6M, reports positive CIndU data, discontinues LR-MDS
Net loss $18.6M ($1.24 diluted EPS); cash $92.5M at Sept 30, 2024.
Jasper reports 93% clinical response rate in SPOTLIGHT study of briquilimab in CIndU
14 of 15 patients (93%) achieved clinical response; 10 of 12 (83%) in 120mg cohort had complete response.
Jasper Therapeutics appoints Svetlana Lucas to Board; Anna French resigns
Anna French resigned from Board effective June 18, 2024, citing no disagreement with company.
Stockholders voted 10.3M for, 95K against to approve 2024 Equity Incentive Plan.
On May 15, 2026 (the “Notice Date”), Christian Nolet informed the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) that he is resigning from the Board and the committees of the Board on which he serves, effective as of the Notice Date.
On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.
Effective immediately following Dr. French’s resignation, on June 18, 2024, the Board appointed Svetlana Lucas, Ph.D. as a Class III director of the Company.
Max materiality 0.85 · Median 0.75 · Most common event other_material